Answers are grounded in this paper and cite their sources.
Background: genetic polymorphism and CYP2D6 activity, as well as haloperidol efficacy and safety rates. Purpose: genetic polymorphism with the steady-state concentration of haloperidol in patients with acute alcohol-induced psychotic disorders (AIPDs). Material and methods: The study involved 100 male patients with AIPD (average age 41.4 ± 14.4 years) who received haloperidol by injections in a dose of 5-10 mg/day. The efficacy profile was assessed using a validated psychometric PANSS scale (Positive and Negative Syndrome Scale). Therapy safety was assessed using the internationally validated UKU (Side-Effect Rating Scale) and SAS (Simpson-Angus Scale for Extrapyramidal Symptoms) scales. Genotyping was performed with the real-time polymerase chain reaction. Conclusion: genetic polymorphism has a statistically significant effect on the steady-state concentration of haloperidol.
No takes yet. Share an insight, caveat, or question.
Parkhomenko et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: